Rectal Ulcer and Perianal Fistula in a Cancer Patient on Immune Checkpoint Inhibitor Therapy

Christine Catinis; Nitish Mittal; Maya Sarihan; Abdullah Aleem; Jianbo Wang; Matthew T. Campbell; Yinghong Wang

doi:10.1007/978-3-031-83533-9_22

Rectal Ulcer and Perianal Fistula in a Cancer Patient on Immune Checkpoint Inhibitor Therapy

Christine Catinis
, Nitish Mittal
, Maya Sarihan
, Abdullah Aleem
, Jianbo Wang
, Matthew T. Campbell
, Yinghong Wang

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

This is a case with metastatic renal cell carcinoma on nivolumab/ipilimumab and cabozantinib who presented with progressively worsening diarrhea and was found to have duodenitis, rectal ulcer, and perianal fistula/fluid collection. He was treated with antibiotics, budesonide, and 3 doses of vedolizumab with significant symptom response and resolution of fistula on follow up imaging 3 weeks later. He was successfully resumed on cabozantinib and remained on nivolumab during the entire GI event.

Original language	English (US)
Title of host publication	Challenging Cases in Immunotherapy Related Organ Toxicities
Publisher	Springer Science+Business Media
Pages	159-165
Number of pages	7
ISBN (Electronic)	9783031835339
ISBN (Print)	9783031835322
DOIs	https://doi.org/10.1007/978-3-031-83533-9_22
State	Published - Jan 1 2025

Keywords

Adverse event
Fistula
Immune checkpoint inhibitors
Immune-mediated
Toxicity
Ulcer

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-031-83533-9_22

Cite this

@inbook{62cebdb0995b4c628ac61cf3f4ef2173,

title = "Rectal Ulcer and Perianal Fistula in a Cancer Patient on Immune Checkpoint Inhibitor Therapy",

abstract = "This is a case with metastatic renal cell carcinoma on nivolumab/ipilimumab and cabozantinib who presented with progressively worsening diarrhea and was found to have duodenitis, rectal ulcer, and perianal fistula/fluid collection. He was treated with antibiotics, budesonide, and 3 doses of vedolizumab with significant symptom response and resolution of fistula on follow up imaging 3 weeks later. He was successfully resumed on cabozantinib and remained on nivolumab during the entire GI event.",

keywords = "Adverse event, Fistula, Immune checkpoint inhibitors, Immune-mediated, Toxicity, Ulcer",

author = "Christine Catinis and Nitish Mittal and Maya Sarihan and Abdullah Aleem and Jianbo Wang and Campbell, \{Matthew T.\} and Yinghong Wang",

note = "Publisher Copyright: {\textcopyright} 2025 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG.",

year = "2025",

month = jan,

day = "1",

doi = "10.1007/978-3-031-83533-9\_22",

language = "English (US)",

isbn = "9783031835322",

pages = "159--165",

booktitle = "Challenging Cases in Immunotherapy Related Organ Toxicities",

publisher = "Springer Science+Business Media",

}

TY - CHAP

T1 - Rectal Ulcer and Perianal Fistula in a Cancer Patient on Immune Checkpoint Inhibitor Therapy

AU - Catinis, Christine

AU - Mittal, Nitish

AU - Sarihan, Maya

AU - Aleem, Abdullah

AU - Wang, Jianbo

AU - Campbell, Matthew T.

AU - Wang, Yinghong

PY - 2025/1/1

Y1 - 2025/1/1

N2 - This is a case with metastatic renal cell carcinoma on nivolumab/ipilimumab and cabozantinib who presented with progressively worsening diarrhea and was found to have duodenitis, rectal ulcer, and perianal fistula/fluid collection. He was treated with antibiotics, budesonide, and 3 doses of vedolizumab with significant symptom response and resolution of fistula on follow up imaging 3 weeks later. He was successfully resumed on cabozantinib and remained on nivolumab during the entire GI event.

AB - This is a case with metastatic renal cell carcinoma on nivolumab/ipilimumab and cabozantinib who presented with progressively worsening diarrhea and was found to have duodenitis, rectal ulcer, and perianal fistula/fluid collection. He was treated with antibiotics, budesonide, and 3 doses of vedolizumab with significant symptom response and resolution of fistula on follow up imaging 3 weeks later. He was successfully resumed on cabozantinib and remained on nivolumab during the entire GI event.

KW - Adverse event

KW - Fistula

KW - Immune checkpoint inhibitors

KW - Immune-mediated

KW - Toxicity

KW - Ulcer

UR - https://www.scopus.com/pages/publications/105022223698

UR - https://www.scopus.com/pages/publications/105022223698#tab=citedBy

U2 - 10.1007/978-3-031-83533-9_22

DO - 10.1007/978-3-031-83533-9_22

M3 - Chapter

AN - SCOPUS:105022223698

SN - 9783031835322

SP - 159

EP - 165

BT - Challenging Cases in Immunotherapy Related Organ Toxicities

PB - Springer Science+Business Media

ER -

Rectal Ulcer and Perianal Fistula in a Cancer Patient on Immune Checkpoint Inhibitor Therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this